Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study
暂无分享,去创建一个
M. Taskinen | D. Gordin | C. Forsblom | P. Groop | V. Harjutsalo | L. Thorn | J. Wadén | N. Tolonen | V. Mäkinen | K. Hietala | J. Kytö | P. Groop | Ville-Petteri Makinen | P. Summanen | N. Tolonen | J. Kytö | P. A. Summanen | J. Wadén
[1] C. Forsblom,et al. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes , 2013, Diabetologia.
[2] T. Wong,et al. Lipids and diabetic retinopathy , 2012, Expert opinion on biological therapy.
[3] P. Dodson,et al. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies , 2011, Eye.
[4] M. Hermans. Non-invited Review: Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD , 2011, Diabetes & vascular disease research.
[5] J. Shaw,et al. Serum Apolipoprotein AI and B Are Stronger Biomarkers of Diabetic Retinopathy Than Traditional Lipids , 2011, Diabetes Care.
[6] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.
[7] E. Agardh,et al. Plasma lipids and plasma lipoproteins in diabetics with and without proliferative retinopathy. , 2009, Acta medica Scandinavica.
[8] Ronald Klein,et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.
[9] H. Parving,et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.
[10] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[11] M. Taskinen,et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes , 2007, Diabetologia.
[12] I. M. Vertkin,et al. Risk Factors , 2007, Morality and Ethics at War.
[13] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[14] D. Lackland,et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.
[15] C. Forsblom,et al. Implementation of guidelines for the prevention of diabetic nephropathy. , 2004, Diabetes care.
[16] A. Albert,et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. , 2001, Diabetes care.
[17] S. Bandinelli,et al. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[18] T. Orchard,et al. Can clinical factors estimate insulin resistance in type 1 diabetes? , 2000, Diabetes.
[19] F. Ferris,et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. , 1999, American journal of ophthalmology.
[20] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[21] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[22] F. Ferris,et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. , 1998, Investigative ophthalmology & visual science.
[23] A. Sjølie,et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.
[24] Stephen J. Aldington,et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. , 1997, Ophthalmology.
[25] The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial , 1995, Diabetes.
[26] L. Kuller,et al. Predictors of Microalbuminuria in Individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study , 1993, Diabetes Care.
[27] H. Chase,et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. , 1993, Ophthalmology.
[28] B. Sinav,et al. Plasma lipids and lipoproteins in retinopathy of type I (insulin-dependent) diabetic patients. , 1993, Annals of ophthalmology.
[29] R. Klein,et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. , 1991, American journal of epidemiology.
[30] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[31] W. Burger,et al. Risk factors for the development of retinopathy in children and adolescents with Type 1 (insulin-dependent) diabetes mellitus , 2006, Diabetologia.
[32] T. Sano,et al. [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[33] R. Klein,et al. THE EPIDEMIOLOGY OF DIABETIC RETINOPATHY: FINDINGS FROM THE WISCONSIN EPIDEMIOLOGIC STUDY OF DIABETIC RETINOPATHY , 1987, International ophthalmology clinics.
[34] Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. , 1981, Ophthalmology.